The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways

被引：0

作者：

Vaishalee P. Kenkre

Brad S. Kahl

机构：

[1] University of Wisconsin,Department of Medicine, Division of Hematology/Oncology

[2] University of Wisconsin,undefined

[3] University of Wisconsin School of Medicine and Public Health,undefined

[4] UW Carbone Cancer Center,undefined

来源：

Current Hematologic Malignancy Reports | 2012年 / 7卷

关键词：

Non-Hodgkin lymphoma; B cell receptor; Targeted therapy; Spleen tyrosine kinase (Syk); Bruton’s tyrosine kinase (BTK); phosphoinositide 3-kinase (PI3K);

D O I：

暂无

中图分类号：

学科分类号：

摘要：

It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton’s tyrosine kinase (BTK), and phosphoinositide 3-kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.

引用

页码：216 / 220

页数：4